Free Trial

60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis

+0.01 (+3.61%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.31 million shs
Average Volume
324,989 shs
Market Capitalization
$3.52 million
P/E Ratio
Dividend Yield
Price Target

60 Degrees Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
735.9% Upside
$2.40 Price Target
Short Interest
1.31% of Float Sold Short
Dividend Strength
News Sentiment
0.46mentions of 60 Degrees Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.56) to ($0.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.05 out of 5 stars

SXTP stock logo

About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.

SXTP Stock Price History

SXTP Stock News Headlines

60 Degrees Shares Plumb New Lows After Public Offering
60 Degrees Pharmaceuticals Inc
Why Is 60 Degrees (SXTP) Stock Down 33% Today?
See More Headlines
Receive SXTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($0.22) per share


Free Float
Market Cap
$3.52 million
Not Optionable
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Geoffrey Stuart Dow (Age 50)
    Chairman, CEO & President
    Comp: $125.56k
  • Mr. Tyrone Miller (Age 49)
    CFO & Treasurer
    Comp: $135.63k
  • Dr. Bryan Smith (Age 58)
    Chief Medical Officer
  • Ms. Kristen Landon (Age 57)
    Chief Commercial Officer
  • Ms. Jennifer Herz

SXTP Stock Analysis - Frequently Asked Questions

Should I buy or sell 60 Degrees Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 60 Degrees Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SXTP shares.
View SXTP analyst ratings
or view top-rated stocks.

What is 60 Degrees Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued twelve-month target prices for 60 Degrees Pharmaceuticals' shares. Their SXTP share price targets range from $2.40 to $2.40. On average, they predict the company's stock price to reach $2.40 in the next twelve months. This suggests a possible upside of 735.9% from the stock's current price.
View analysts price targets for SXTP
or view top-rated stocks among Wall Street analysts.

How have SXTP shares performed in 2024?

60 Degrees Pharmaceuticals' stock was trading at $1.02 on January 1st, 2024. Since then, SXTP shares have decreased by 71.9% and is now trading at $0.2871.
View the best growth stocks for 2024 here

When is 60 Degrees Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 23rd 2024.
View our SXTP earnings forecast

How were 60 Degrees Pharmaceuticals' earnings last quarter?

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) released its quarterly earnings data on Monday, April, 1st. The company reported ($0.44) EPS for the quarter. The firm had revenue of ($0.10) million for the quarter, compared to analyst estimates of $0.06 million.

When did 60 Degrees Pharmaceuticals IPO?

60 Degrees Pharmaceuticals (SXTP) raised $7 million in an initial public offering on Wednesday, July 12th 2023. The company issued 1,400,000 shares at $5.30 per share. WallachBeth Capital LLC served as the underwriter for the IPO.

Who are 60 Degrees Pharmaceuticals' major shareholders?

60 Degrees Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Central Bank & Trust Co. (4.61%).

How do I buy shares of 60 Degrees Pharmaceuticals?

Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SXTP) was last updated on 5/22/2024 by Staff

From Our Partners